No Data
No Data
Express News | INVO Bioscience: On June 18, 2024, Co Received Notice From Nasdaq Informing Co Was Granted Request for Continued Listing on Nasdaq
INVO Bioscience Files for $100M Mixed Shelf
INNO BioScience Shares Are Trading Higher After the Company Reported a Year-over-year Increase in Q1 EPS Results.
INVO Bioscience (INVO.US): The 2024 Q1 financial report achieved revenue of US$1,576 million, previous value of US$348.03 million; earnings per share were -0.42 USD, prior value of -4.00 USD.
INVO Bioscience (INVO.US): The 2024 Q1 financial report achieved revenue of US$1,576 million, previous value of US$348.03 million; earnings per share were -0.42 USD, prior value of -4.00 USD.
INVO Bioscience Q1 EPS $(0.42), Sales $1.58M Up From $348.02K YoY
Invo BioScience 1Q Rev $1.58M >INVO
No Data